Skip to main content

Podcast

Rheumatology Believe It or Not (4.25.2025)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Should we believe the reviews and metanalyses?

Osteoarthritis Risky Business (4.18.2025)

Dr. Jack Cush reviews the news and Journal reports from this week on RheumNow.com. Osteoarthritis patients have unique risks and synovial fluid WBC numbers can tell you when to worry about septic arthritis in gout and pseudogout patients.

EMR Messaging Woes (4.11.2025)

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com

An Epidural Letdown (4.4.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. **Correction: a Tweet from 3/18 podcast, had incorrect information. Late Breaking abstract from 2025 Amer. Acad.

Biomarkers in RA

Rheumatologist Dr. Walter Maksymowych discusses the role of biomarkers in RA care, with a focus on 14-3-3eta as a modifiable marker for diagnosis and monitoring disease progression.

Cancer Survival with TNF Inhibitors (3.28.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

ERA, APPs, & Alpha GAL (3.21.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Listen in for 2 new case questions - Ask Cush Anything.

World Changers (3.14.2025)

Dr Jack Cush and his podcast friends are out to change the world. Here is his weekly review of the news and journal reports from the past week on RheumNow.com

Autoimmune Myositis The Role of the Laboratory in Diagnosis and Phenotyping Sponsored by LabCorp

Hear from rheumatologist Stanley J. Naides MD, FACP, FACR, as he details the clinical features of autoimmune myositis, the associated phenotypes and autoantibodies, plus the methodologies and testing options to support a myositis diagnosis.

EXXELERATE: New Thoughts on High RF Titer Sponsored by: UCB

Two leading rheumatologists share insights into why RF levels are important to consider when identifying treatment options for patients with RA.

Hydroxychloro-King (3.7.2025)

Dr. Jack Cush reviews the news, journal reports and regulatory actions from the past week on RheumNow.com

Treatment goals for RA- Is it time to transition to MOAs? Sponsored by AbbVie Medical Affairs

Treatment goals for RA- Is it time to transition to MOAs? Sponsored by AbbVie Medical Affairs by Dr. Cush
×